Biocon Biologics signs settlement agreement with Janssen to launch Biosimilar Bmab 1200 in multiple countries
Biocon Biologics Share Price | Stelara (Ustekinumab) is a monoclonal antibody medication that targets interleukin IL-12/23, which is involved in immune responses related to conditions such as psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.